Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Maas

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
International Journal of Molecular Sciences|March 29, 2023
Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and MetastasesMoritz Maas, Aymone Kurcz, Jörg Hennenlotter, et al.
Disease Markers|April 14, 2018
Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?Simone Bier, Jörg Hennenlotter, Michael Esser, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 9, 2021
Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancerSimon Walz, Qingqing Wang, Xinjie Zhao, et al.
European Urology Focus|May 8, 2021
Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder CancerMoritz Maas, Steffen Rausch, Teresa Guttenberg, et al.
BJU International|March 16, 2018
Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancerGiorgio I Russo, Simone Bier, Jörg Hennenlotter, et al.
Urologia Internationalis|January 21, 2024
An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder CancerMoritz J Reike, Alina Reicherz, Karl H Tully, et al.
The Journal of Urology|May 20, 2026
Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-GuérinHenning Bahlburg, Moritz Maas, Alberto Contreras-Sanz, et al.
BJU International|July 9, 2025
Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancerMarkus von Deimling, Marc Furrer, Alberto Bianchi, et al.
BJU International|October 31, 2023
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancerMarkus von Deimling, Marc Furrer, Laura S Mertens, et al.
BJU International|March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancerMarkus von Deimling, Laura S Mertens, Marc Furrer, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
International Journal of Molecular Sciences|March 29, 2023
Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and MetastasesMoritz Maas, Aymone Kurcz, Jörg Hennenlotter, et al.
Disease Markers|April 14, 2018
Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?Simone Bier, Jörg Hennenlotter, Michael Esser, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 9, 2021
Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancerSimon Walz, Qingqing Wang, Xinjie Zhao, et al.
European Urology Focus|May 8, 2021
Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder CancerMoritz Maas, Steffen Rausch, Teresa Guttenberg, et al.
BJU International|March 16, 2018
Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancerGiorgio I Russo, Simone Bier, Jörg Hennenlotter, et al.
Urologia Internationalis|January 21, 2024
An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder CancerMoritz J Reike, Alina Reicherz, Karl H Tully, et al.
The Journal of Urology|May 20, 2026
Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-GuérinHenning Bahlburg, Moritz Maas, Alberto Contreras-Sanz, et al.
BJU International|July 9, 2025
Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancerMarkus von Deimling, Marc Furrer, Alberto Bianchi, et al.
BJU International|October 31, 2023
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancerMarkus von Deimling, Marc Furrer, Laura S Mertens, et al.
BJU International|March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancerMarkus von Deimling, Laura S Mertens, Marc Furrer, et al.
Pageof 4